| molecular function |
|---|
| | GO:0003677 | | DNA binding | | Any molecular function by which a gene product interacts selectively and non-covalently with DNA (deoxyribonucleic acid). |
| | GO:0070530 | | K63-linked polyubiquitin modification-dependent protein binding | | Interacting selectively and non-covalently with a protein upon poly-ubiquitination formed by linkages between lysine residues at position 63 in the target protein. |
| | GO:0003824 | | catalytic activity | | Catalysis of a biochemical reaction at physiological temperatures. In biologically catalyzed reactions, the reactants are known as substrates, and the catalysts are naturally occurring macromolecular substances known as enzymes. Enzymes possess specific binding sites for substrates, and are usually composed wholly or largely of protein, but RNA that has catalytic activity (ribozyme) is often also regarded as enzymatic. |
| | GO:0008234 | | cysteine-type peptidase activity | | Catalysis of the hydrolysis of peptide bonds in a polypeptide chain by a mechanism in which the sulfhydryl group of a cysteine residue at the active center acts as a nucleophile. |
| | GO:0016787 | | hydrolase activity | | Catalysis of the hydrolysis of various bonds, e.g. C-O, C-N, C-C, phosphoric anhydride bonds, etc. Hydrolase is the systematic name for any enzyme of EC class 3. |
| | GO:0019900 | | kinase binding | | Interacting selectively and non-covalently with a kinase, any enzyme that catalyzes the transfer of a phosphate group. |
| | GO:0016874 | | ligase activity | | Catalysis of the joining of two substances, or two groups within a single molecule, with the concomitant hydrolysis of the diphosphate bond in ATP or a similar triphosphate. |
| | GO:0046872 | | metal ion binding | | Interacting selectively and non-covalently with any metal ion. |
| | GO:0008233 | | peptidase activity | | Catalysis of the hydrolysis of a peptide bond. A peptide bond is a covalent bond formed when the carbon atom from the carboxyl group of one amino acid shares electrons with the nitrogen atom from the amino group of a second amino acid. |
| | GO:0002020 | | protease binding | | Interacting selectively and non-covalently with any protease or peptidase. |
| | GO:0005515 | | protein binding | | Interacting selectively and non-covalently with any protein or protein complex (a complex of two or more proteins that may include other nonprotein molecules). |
| | GO:0043621 | | protein self-association | | Interacting selectively and non-covalently with a domain within the same polypeptide. |
| | GO:0004843 | | thiol-dependent ubiquitin-specific protease activity | | Catalysis of the thiol-dependent hydrolysis of a peptide bond formed by the C-terminal glycine of ubiquitin and another protein. |
| | GO:0036459 | | thiol-dependent ubiquitinyl hydrolase activity | | Catalysis of the thiol-dependent hydrolysis of an ester, thioester, amide, peptide or isopeptide bond formed by the C-terminal glycine of ubiquitin. |
| | GO:0043130 | | ubiquitin binding | | Interacting selectively and non-covalently with ubiquitin, a protein that when covalently bound to other cellular proteins marks them for proteolytic degradation. |
| | GO:0004842 | | ubiquitin-protein transferase activity | | Catalysis of the transfer of ubiquitin from one protein to another via the reaction X-Ub + Y --> Y-Ub + X, where both X-Ub and Y-Ub are covalent linkages. |
| | GO:0008270 | | zinc ion binding | | Interacting selectively and non-covalently with zinc (Zn) ions. |
| biological process |
|---|
| | GO:0001922 | | B-1 B cell homeostasis | | The process of regulating the proliferation and elimination of B cells of the B-1 subset such that the total number of B-1 B cells within a whole or part of an organism is stable over time in the absence of an outside stimulus. B-1 B cells are a distinct subset of B cells characterized as being CD5 positive, found predominantly in the peritoneum, pleural cavities, and spleen, and enriched for self-reactivity. |
| | GO:0006915 | | apoptotic process | | A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died. |
| | GO:0070301 | | cellular response to hydrogen peroxide | | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hydrogen peroxide (H2O2) stimulus. |
| | GO:0071222 | | cellular response to lipopolysaccharide | | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lipopolysaccharide stimulus; lipopolysaccharide is a major component of the cell wall of gram-negative bacteria. |
| | GO:0072666 | | establishment of protein localization to vacuole | | The directed movement of a protein to a specific location in a vacuole. |
| | GO:0006954 | | inflammatory response | | The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. |
| | GO:0008152 | | metabolic process | | The chemical reactions and pathways, including anabolism and catabolism, by which living organisms transform chemical substances. Metabolic processes typically transform small molecules, but also include macromolecular processes such as DNA repair and replication, and protein synthesis and degradation. |
| | GO:0050869 | | negative regulation of B cell activation | | Any process that stops, prevents, or reduces the frequency, rate or extent of B cell activation. |
| | GO:2000349 | | negative regulation of CD40 signaling pathway | | Any process that stops, prevents or reduces the frequency, rate or extent of signaling via the CD40 signaling pathway. |
| | GO:0043124 | | negative regulation of I-kappaB kinase/NF-kappaB signaling | | Any process that stops, prevents, or reduces the frequency, rate or extent of -kappaB kinase/NF-kappaB signaling. |
| | GO:0032088 | | negative regulation of NF-kappaB transcription factor activity | | Any process that stops, prevents, or reduces the frequency, rate or extent of the activity of the transcription factor NF-kappaB. |
| | GO:0045779 | | negative regulation of bone resorption | | Any process that stops, prevents, or reduces the frequency, rate or extent of bone resorption. |
| | GO:0060548 | | negative regulation of cell death | | Any process that decreases the rate or frequency of cell death. Cell death is the specific activation or halting of processes within a cell so that its vital functions markedly cease, rather than simply deteriorating gradually over time, which culminates in cell death. |
| | GO:0002677 | | negative regulation of chronic inflammatory response | | Any process that stops, prevents, or reduces the frequency, rate, or extent of a chronic inflammatory response. |
| | GO:0045736 | | negative regulation of cyclin-dependent protein serine/threonine kinase activity | | Any process that stops, prevents, or reduces the frequency, rate or extent of cyclin-dependent protein serine/threonine kinase activity. |
| | GO:2000352 | | negative regulation of endothelial cell apoptotic process | | Any process that stops, prevents or reduces the frequency, rate or extent of endothelial cell apoptotic process. |
| | GO:1902042 | | negative regulation of extrinsic apoptotic signaling pathway via death domain receptors | | Any process that stops, prevents or reduces the frequency, rate or extent of extrinsic apoptotic signaling pathway via death domain receptors. |
| | GO:0050728 | | negative regulation of inflammatory response | | Any process that stops, prevents, or reduces the frequency, rate or extent of the inflammatory response. |
| | GO:0045824 | | negative regulation of innate immune response | | Any process that stops, prevents, or reduces the frequency, rate or extent of the innate immune response. |
| | GO:0032691 | | negative regulation of interleukin-1 beta production | | Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-1 beta production. |
| | GO:0032703 | | negative regulation of interleukin-2 production | | Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-2 production. |
| | GO:0032715 | | negative regulation of interleukin-6 production | | Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-6 production. |
| | GO:0070429 | | negative regulation of nucleotide-binding oligomerization domain containing 1 signaling pathway | | Any process that stops, prevents, or reduces the frequency, rate, or extent of the nucleotide-binding oligomerization domain containing 1 (NOD1) pathway. |
| | GO:0070433 | | negative regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway | | Any process that stops, prevents, or reduces the frequency, rate, or extent of the nucleotide-binding oligomerization domain containing 2 (NOD2) pathway. |
| | GO:0090291 | | negative regulation of osteoclast proliferation | | Any process that decreases the rate, frequency, or extent of the multiplication or reproduction of osteoclasts, resulting in the expansion of an osteoclast cell population. |
| | GO:0031397 | | negative regulation of protein ubiquitination | | Any process that stops, prevents, or reduces the frequency, rate or extent of the addition of ubiquitin groups to a protein. |
| | GO:0048662 | | negative regulation of smooth muscle cell proliferation | | Any process that stops, prevents or reduces the rate or extent of smooth muscle cell proliferation. |
| | GO:0034136 | | negative regulation of toll-like receptor 2 signaling pathway | | Any process that stops, prevents, or reduces the frequency, rate, or extent of toll-like receptor 2 signaling pathway. |
| | GO:0034140 | | negative regulation of toll-like receptor 3 signaling pathway | | Any process that stops, prevents, or reduces the frequency, rate, or extent of toll-like receptor 3 signaling pathway. |
| | GO:0034144 | | negative regulation of toll-like receptor 4 signaling pathway | | Any process that stops, prevents, or reduces the frequency, rate, or extent of toll-like receptor 4 signaling pathway. |
| | GO:0034148 | | negative regulation of toll-like receptor 5 signaling pathway | | Any process that stops, prevents, or reduces the frequency, rate, or extent of toll-like receptor 5 signaling pathway. |
| | GO:0032720 | | negative regulation of tumor necrosis factor production | | Any process that stops, prevents, or reduces the frequency, rate, or extent of tumor necrosis factor production. |
| | GO:0032480 | | negative regulation of type I interferon production | | Any process that stops, prevents, or reduces the frequency, rate, or extent of type I interferon production. Type I interferons include the interferon-alpha, beta, delta, episilon, zeta, kappa, tau, and omega gene families. |
| | GO:0070423 | | nucleotide-binding oligomerization domain containing signaling pathway | | Any series of molecular signals generated as a consequence of binding to a nucleotide-binding oligomerization domain containing (NOD) protein. |
| | GO:1903364 | | positive regulation of cellular protein catabolic process | | Any process that activates or increases the frequency, rate or extent of cellular protein catabolic process. |
| | GO:2000347 | | positive regulation of hepatocyte proliferation | | Any process that activates or increases the frequency, rate or extent of hepatocyte proliferation. |
| | GO:0045732 | | positive regulation of protein catabolic process | | Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of a protein by the destruction of the native, active configuration, with or without the hydrolysis of peptide bonds. |
| | GO:0035871 | | protein K11-linked deubiquitination | | A protein deubiquitination process in which a K11-linked ubiquitin chain, i.e. a polymer of ubiquitin formed by linkages between lysine residues at position 11 of the ubiquitin monomers, is removed from a protein. |
| | GO:0071108 | | protein K48-linked deubiquitination | | A protein deubiquitination process in which a K48-linked ubiquitin chain, i.e. a polymer of ubiquitin formed by linkages between lysine residues at position 48 of the ubiquitin monomers, is removed from a protein. |
| | GO:0070936 | | protein K48-linked ubiquitination | | A protein ubiquitination process in which a polymer of ubiquitin, formed by linkages between lysine residues at position 48 of the ubiquitin monomers, is added to a protein. K48-linked ubiquitination targets the substrate protein for degradation. |
| | GO:0070536 | | protein K63-linked deubiquitination | | A protein deubiquitination process in which a K63-linked ubiquitin chain, i.e. a polymer of ubiquitin formed by linkages between lysine residues at position 63 of the ubiquitin monomers, is removed from a protein. |
| | GO:0016579 | | protein deubiquitination | | The removal of one or more ubiquitin groups from a protein. |
| | GO:0071947 | | protein deubiquitination involved in ubiquitin-dependent protein catabolic process | | The removal of one or more ubiquitin groups from a protein as part of a process of ubiquitin-dependent protein catabolism. |
| | GO:0051259 | | protein oligomerization | | The process of creating protein oligomers, compounds composed of a small number, usually between three and ten, of component monomers; protein oligomers may be composed of different or identical monomers. Oligomers may be formed by the polymerization of a number of monomers or the depolymerization of a large protein polymer. |
| | GO:0016567 | | protein ubiquitination | | The process in which one or more ubiquitin groups are added to a protein. |
| | GO:0006508 | | proteolysis | | The hydrolysis of proteins into smaller polypeptides and/or amino acids by cleavage of their peptide bonds. |
| | GO:0050691 | | regulation of defense response to virus by host | | Any host process that modulates the frequency, rate, or extent of the antiviral response of a host cell or organism. |
| | GO:0002634 | | regulation of germinal center formation | | Any process that modulates the frequency, rate, or extent of germinal center formation. |
| | GO:0050727 | | regulation of inflammatory response | | Any process that modulates the frequency, rate or extent of the inflammatory response, the immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. |
| | GO:0010803 | | regulation of tumor necrosis factor-mediated signaling pathway | | Any process that modulates the rate or extent of the tumor necrosis factor-mediated signaling pathway. The tumor necrosis factor-mediated signaling pathway is the series of molecular signals generated as a consequence of tumor necrosis factor binding to a cell surface receptor. |
| | GO:0061043 | | regulation of vascular wound healing | | Any process that modulates the rate, frequency, or extent of blood vessel formation when new vessels emerge from the proliferation of pre-existing blood vessels and contribute to the series of events that restore integrity to damaged vasculature. |
| | GO:0002237 | | response to molecule of bacterial origin | | Any process that results in a change in state or activity of an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus by molecules of bacterial origin such as peptides derived from bacterial flagellin. |
| | GO:0032495 | | response to muramyl dipeptide | | Any process that results in a change in state or activity of an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a muramyl dipeptide stimulus. Muramyl dipeptide is derived from peptidoglycan. |
| | GO:0072573 | | tolerance induction to lipopolysaccharide | | Tolerance induction directed at lipopolysaccharide antigens. |
| cellular component |
|---|
| | GO:0005737 | | cytoplasm | | All of the contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. |
| | GO:0005829 | | cytosol | | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. |
| | GO:0070062 | | extracellular exosome | | A vesicle that is released into the extracellular region by fusion of the limiting endosomal membrane of a multivesicular body with the plasma membrane. Extracellular exosomes, also simply called exosomes, have a diameter of about 40-100 nm. |
| | GO:0005764 | | lysosome | | A small lytic vacuole that has cell cycle-independent morphology and is found in most animal cells and that contains a variety of hydrolases, most of which have their maximal activities in the pH range 5-6. The contained enzymes display latency if properly isolated. About 40 different lysosomal hydrolases are known and lysosomes have a great variety of morphologies and functions. |
| | GO:0005634 | | nucleus | | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. |
Description
